^
    Back
    Association details:
    Biomarker:CD133 rs3130
    Cancer:Colorectal Cancer
    Drug:Avastin (bevacizumab) (VEGF-A inhibitor)
    Direction:Resistant
    Evidence:
    Evidence Level:
    Resistant: C3 – Early Trials
    New
    Source:
    Cancer Biomark
    Title:

    Association of CD133 polymorphisms and response to bevacizumab in patients with metastatic colorectal cancer

    Excerpt:
    The rs3130 CC genotype was associated with reduced toxicity of treatments (p= 0.0017), and with lower overall survival on bevacizumab (p= 0.002).
    DOI:
    10.3233/CBM-150528